Cerulean Pharma (Nasdaq: CERU) Shares Rise on Sale Speculation

Cerulean Pharma, Inc. – Nasdaq: CERU

An announcement by the Board of Cerulean Pharma to explore strategic alternatives has sent shares higher on speculation that a sale may be in the works. CERU, traded on the Nasdaq under ticker CERU, ended trading Thursday at $0.93 and have reached a high of $1.49 in early trading on heavy volumes. The announcement was likely due to a Phase 2 clinical trial failure, in August, which led to Cerulean cutting half its workforce.

Waltham, MA-based Cerulean Pharma develops products to improve treatment options for cancer victims. The company developed the Dynamic Tumor Targeting™ Platform designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Cerulean’s lead platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials. Our lead indication is ovarian cancer. Our second platform-generated NDC clinical candidate, CRLX301, is in Phase 2a clinical development for the treatment of advanced solid tumors.

Cerulean sales peaked in 2012 when the company posted a figure of $600k. No sales were reported for 2015. CERU shares have never experienced positive EPS – losing more than $1.20 EPS in each of the past five years. CERU lost $1.56 EPS in 2015. Three firms rate CEU shares. One rates them as a “Strong Buy”, and the other rates CERU as a “Hold”. Their consensus price target is $1.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol CERU
Last Price a/o 9:23 AM EST  $                      1.34
Average Volume                    328,570
Market Cap (mlns)  $                    25.49
Sales (mlns)
Shares Outstanding (mlns) 27.38
Share Float (mlns) 24.66
Shortable Yes
Optionable Yes
Inside Ownership 1.30%
Short Float 2.68%
Short Interest Ratio 2.01
Quarterly Return 24.82%
YTD Return 31.46%
Year Return -58.99%

Benitec Biopharma (Nasdaq: BNTC) Doubles!

Benitec Biopharma Limited – Nasdaq: BNTC

Shares of Benitec Bipharma are more than double yesterday’s closing price and surged to an inter-day high of $4.44 before settling down to $3.50 in mid-day trading. BNTC, traded on the Nasdaq, shares normally have an average daily volume of less than 200k, but today more than seven million shares have traded almost two hours before market close.

The Australian-based company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases. Benitec Biopharma is a biotechnology company developing a proprietary therapeutic technology platform that combines gene silencing and gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec Biopharma is using DNA-directed RNA interference, or ddRNAi, to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases, such as hepatitis B, age-related macular degeneration, or AMD and oculopharyngeal muscular dystrophy, or OPMD.

Benitec Biopharma has no reported sales. BNTC has no EPS. Only one firm rates BNTC shares it gives it a rating of “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol BNTC
Last Price a/o 1:28 PM EST  $                      3.45
Average Volume                    176,560
Market Cap (mlns)  $                  234.45
Sales (mlns) $7.19
Shares Outstanding (mlns) 146.53
Share Float (mlns) 5.49
Shortable Yes
Optionable No
Inside Ownership
Short Float 0.49%
Short Interest Ratio 0.15
Quarterly Return 7.53%
YTD Return 4.58%
Year Return -54.29%